JP2018520124A - Ｎｕｔ正中線癌の治療 - Google Patents

Ｎｕｔ正中線癌の治療 Download PDF

Info

Publication number
JP2018520124A
JP2018520124A JP2017563973A JP2017563973A JP2018520124A JP 2018520124 A JP2018520124 A JP 2018520124A JP 2017563973 A JP2017563973 A JP 2017563973A JP 2017563973 A JP2017563973 A JP 2017563973A JP 2018520124 A JP2018520124 A JP 2018520124A
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
cycloalkyl
substituted
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017563973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520124A5 (enExample
Inventor
ランドー，スティーブン，ビー．
ケーギー，マイケル，エイチ．
Original Assignee
テンシャ セラピューティクス，インコーポレイテッド
テンシャ セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テンシャ セラピューティクス，インコーポレイテッド, テンシャ セラピューティクス，インコーポレイテッド filed Critical テンシャ セラピューティクス，インコーポレイテッド
Publication of JP2018520124A publication Critical patent/JP2018520124A/ja
Publication of JP2018520124A5 publication Critical patent/JP2018520124A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57557—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017563973A 2015-06-26 2016-06-24 Ｎｕｔ正中線癌の治療 Pending JP2018520124A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185203P 2015-06-26 2015-06-26
US62/185,203 2015-06-26
PCT/US2016/039270 WO2016210275A1 (en) 2015-06-26 2016-06-24 Treatment of nut midline carcinoma

Publications (2)

Publication Number Publication Date
JP2018520124A true JP2018520124A (ja) 2018-07-26
JP2018520124A5 JP2018520124A5 (enExample) 2019-07-25

Family

ID=56409188

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017563973A Pending JP2018520124A (ja) 2015-06-26 2016-06-24 Ｎｕｔ正中線癌の治療

Country Status (14)

Country Link
US (1) US20180193350A1 (enExample)
EP (1) EP3314005A1 (enExample)
JP (1) JP2018520124A (enExample)
KR (1) KR20180035785A (enExample)
CN (1) CN107787227A (enExample)
AR (1) AR105124A1 (enExample)
AU (1) AU2016283020A1 (enExample)
BR (1) BR112017028178A2 (enExample)
CA (1) CA2989313A1 (enExample)
HK (1) HK1252062A1 (enExample)
IL (1) IL256186A (enExample)
MA (1) MA42249A (enExample)
MX (1) MX2017016337A (enExample)
WO (1) WO2016210275A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2799403C (en) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
PL2571503T3 (pl) 2010-05-14 2015-06-30 Dana Farber Cancer Inst Inc Kompozycje i sposoby leczenia nowotworu, choroby zapalnej i innych zaburzeń
WO2015070020A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
CN106456653A (zh) 2014-02-28 2017-02-22 腾沙治疗公司 高胰岛素血症相关病症的治疗
MX376748B (es) 2014-10-27 2025-03-07 Tensha Therapeutics Inc Inhibidores del bromodominio.
WO2024123929A1 (en) * 2022-12-06 2024-06-13 Bioventures, Llc Development of potent dual hdac/brd4 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532130A (ja) * 2010-05-14 2013-08-15 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CA2710740C (en) 2007-12-28 2016-07-19 Shinji Miyoshi Thienotriazolodiazepine compound as antitumor agent
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
ME02360B (me) 2009-11-05 2016-06-20 Glaxosmithkline Llc Inhibitor bromodomena benzodiazepina
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
BR112012010705A2 (pt) 2009-11-05 2016-03-29 Glaxosmithkline Llc composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio
PL2571503T3 (pl) * 2010-05-14 2015-06-30 Dana Farber Cancer Inst Inc Kompozycje i sposoby leczenia nowotworu, choroby zapalnej i innych zaburzeń
US9085582B2 (en) 2010-06-22 2015-07-21 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
CN106456653A (zh) 2014-02-28 2017-02-22 腾沙治疗公司 高胰岛素血症相关病症的治疗

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532130A (ja) * 2010-05-14 2013-08-15 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 15, no. 18, JPN6020017637, 2010, pages 3763 - 3771, ISSN: 0004275018 *

Also Published As

Publication number Publication date
AU2016283020A1 (en) 2018-01-04
AR105124A1 (es) 2017-09-06
HK1252062A1 (zh) 2019-05-10
MA42249A (fr) 2018-05-02
KR20180035785A (ko) 2018-04-06
MX2017016337A (es) 2018-11-22
IL256186A (en) 2018-02-28
EP3314005A1 (en) 2018-05-02
US20180193350A1 (en) 2018-07-12
CA2989313A1 (en) 2016-12-29
CN107787227A (zh) 2018-03-09
BR112017028178A2 (en) 2018-08-28
WO2016210275A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
JP2018520124A (ja) Ｎｕｔ正中線癌の治療
US7612206B2 (en) Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors
Ory et al. PET radioligands for in vivo visualization of neuroinflammation
TWI791507B (zh) 使用ccr3-抑制劑治療老化相關損傷之方法及組合物
EA038337B1 (ru) Ингибиторы ezh2 для лечения лимфомы
US20180185382A1 (en) Compositions and methods for treating cancer
UA119538C2 (uk) Лікування злоякісної пухлини дигідропіразинопіразинами
EP2136829A1 (en) Kinase protein binding inhibitors
WO2015089495A2 (en) Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders
KR20210027382A (ko) 접히지 않은 단백질 반응의 활성화제
CN110433165A (zh) Akt和mek抑制剂化合物的组合及其使用方法
WO2016040527A1 (en) Metabolism probes for therapy and diagnosis
JP2009537626A (ja) ９−ヒドロキシエリプチシン誘導体による悪性表現型の復帰変異
TWI306401B (en) Benzothiazolium compounds
HUP0302496A2 (hu) Nempeptid bombezinreceptor-antagonisták felhasználása szorongás és pánikbetegség kezelésére
JP2022517517A (ja) 膠芽腫の治療および予防
CN112789044A (zh) 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物
US20250170097A1 (en) Cathepsin inhibitors and use thereof in a method for detecting and treating resistance to immunotherapy
WO2024137506A1 (en) Compositions and methods for improving neurological diseases and disorders
WO2024137478A1 (en) Methods for treating various conditions and indications with agonists and antagonists
CN116801875A (zh) 用于改善神经疾病和病症的组合物和方法
JP6280050B2 (ja) 肥満症予防又は治療剤，リウマチの予防又は治療剤
HK40053020A (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
HK40019123A (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
HK1147417A (en) Kinase protein binding inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201029

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210120